Canaccord Genuity Trims Price Target on Regulus Therapeutics to $11 From $12, Maintains Buy Rating
Canaccord Genuity Trims Price Target on Regulus Therapeutics to $11 From $12, Maintains Buy Rating
Canaccord Genuity將Regulus Therapeutics的目標股價從12美元下調至11美元，維持買入評級
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登入免費觀看全文
登入/註冊
資訊熱榜
更新時間